S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）
Status:
Recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
The study aims to compare the efficacy and safety of S-1 for 9 months versus S-1 for 1 year
as adjuvant chemotherapy after D2 resection in patients with gastric cancer.
Hypothesis: For gastric patients after D2 resection, S-1 for 9 months shows non-inferiority
to S-1 for 1 year in disease-free survival(DFS), overall survival (OS) and safety.